Boston University Charles River Campus
Trial Pipeline
Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients
NCT07455760
Telehealth Exercise and Mindfulness for Pain in Osteoarthritis - Stage 1B
NCT06684587
Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Town, South Africa
NCT05624931
A Pilot Randomized Controlled Trial of the Hopeful and Healthy Living Program
NCT06940843
Positive Minds Strong Joints for Knee Osteoarthritis
NCT06493903
Future Leaders Program: Testing a Youth Leadership, Engagement, and Mindfulness Program
NCT06736522
Neural Mechanisms of Family-Focused Treatment for Youth Depression
NCT06289010
Harness-based Mobility Intervention for Infants With Down Syndrome
NCT06219863
Virtual Reality Intervention for Fear of Heights
NCT06468878
Neuromodulation for a Novel OCD Biomarker and Treatment
NCT05994053
Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation
NCT06094192
Alcohol and "Heat of the Moment" Sexual Decision Making
NCT05729256
Word Learning in Deaf Children Using Eye-tracking and Behavioral Measures
NCT05993832
Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety
NCT05683223
Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech
NCT05437159
Neural Mechanisms of Spatial Representations Beyond the Self
NCT05406349
Improving Spatial Perception and Speech Understanding in Multitalker Mixtures
NCT05260307
Initial Assessment of the Feasibility and Efficacy of a Scalable Digital CBT for Generalized Anxiety and Associated Health Behaviors in a Cardiovascular Disease Population
NCT04895995
Imaging Brain Fluids During Breathing
NCT05180981
College Student Daily Life and Alcohol Use Study
NCT06365125
Conversation Group Treatment for Aphasia: Does it Work?
NCT05113160
A Hybrid Effectiveness Implementation Study of Latino/a Alcohol and Drug Users
NCT04771650
The Benefits of Nature for Mood and Cognition in Persons With and Without Parkinson's Disease
NCT06483126
Neurostimulation Exosuit Augmented Training (NEAT) in the Clinic
NCT07218107
Translation of Robotic Apparel for Alleviating Low Back Pain
NCT05736393
Virtual Reality Intervention for Speech Anxiety
NCT06086756
Responders to Rhythmic Auditory Cueing in Parkinson Disease
NCT05733819
Effectiveness Study of STAR (Sensory Therapies and Research) Intervention for School-Based Occupational Therapy Services for Students With Sensory Processing Challenges
NCT04769674
Flourishing and Virtue in Cognitive-Behavioral Therapy for Anxiety and Depressive Disorders
NCT05120232
Improving Working Memory in Older Adults
NCT04362696
Motivation and Skills Support (MASS)
NCT03404219
Alcohol and Sex Risk Intervention for MSM Supplement
NCT03522948
Bridging Community Gaps Photovoice
NCT03291717
"Recovery 4 US" - A Photovoice-based Social Media Program
NCT03266614
Testing Effectiveness of a Peer-Led Intervention to Enhance Community Integration
NCT02508480
Treatment Study for Non-Suicidal Self-Injury
NCT02060448
Assessing the Effects of a Neurobehavioral Intervention on Symptoms of Obsessive Compulsive Disorder
NCT01414023
Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders
NCT01243606
Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder
NCT00790868
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Therapeutic Areas
What the Pipeline for Boston University Charles River Campus Shows
According to the ClinicalTrials.gov registry, Boston University Charles River Campus is linked to 148 US clinical trials across every stage of research activity. Of those, 128 studies are currently recruiting — about 86% of the sponsor's indexed portfolio — and 17 are already marked complete, representing roughly 11% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Boston University Charles River Campus reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Boston University Charles River Campus is Anxiety Disorders with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.